{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-001164","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.573380+00:00","generated_at":"2026-05-17T17:09:30.191146+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunic Q2 net loss $27M; vidofludimus reduces disability worsening 24% in PMS trial","bullets":["Net loss of $27.0M ($0.20/share) for Q2 2025 vs $21.4M ($0.21/share) in Q2 2024.","Cash and equivalents $55.3M; company states insufficient liquidity for 12 months without additional capital.","Phase 2 CALLIPER: vidofludimus calcium reduced 24-week confirmed disability worsening 23.8% overall, 31.3% in PPMS.","Phase 3 ENSURE enrollment completed (1,121 and 1,100 patients); top-line data expected by end of 2026.","Two financings raised $70.1M gross in Q2 2025; R&D expenses $21.4M (+$3.0M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-001164","json":"https://secwatch.observer/filing/0001193805-25-001164.json","markdown":"https://secwatch.observer/filing/0001193805-25-001164.md","text":"https://secwatch.observer/filing/0001193805-25-001164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/0001193805-25-001164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/e664768_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:09:30.191146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}